EASI-75
FIGURE 1 · Panel A
Panel A 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Yan Zhao, Litao Zhang, Liming Wu, Bin Yang, Jinyan Wang, Yumei Li, Qingchun Diao, Jingyi Li, Qing Sun, Xiaohong Zhu, Xiaoyong Man, Lihua Wang, Yanyan Feng, Tao Cai, Huiming Zeng, Linfeng Li, Jianyun Lu, Hong Ren, Fuqiu Li, Qianjin Lu, Xiaohua Tao, Rong Xiao, Chao Ji, Jing Sun, Yanping Qiu, Bo Chen, Jianzhong Zhang
Int J Dermatol 65(6) 1185-1194
BACKGROUND: Elderly patients with moderate-to-severe atopic dermatitis (AD) often exhibit more heterogeneous inflammatory profiles compared with younger adults. To evaluate the efficacy and safety of stapokibart, an anti-interleukin-4 receptor α subunit (IL-4Rα) monoclonal antibody, in different age subgroups. METHODS: Eligible adults were randomized to receive subcutaneous stapokibart 300 mg every 2 weeks (Q2W; loading dose 600 mg) or placebo for 16 weeks. All patients subsequently received stapokibart 300 mg Q2W for 36 weeks. In this post hoc analysis, patients were classified as elderly (aged ≥ 60 years, n = 93) and non-elderly patients (aged 18 and < 60 years, n = 407). Main efficacy outcomes included ≥ 75% improvement from baseline in Eczema Area and Severity Index (EASI-75), Investigator's Global Assessment (IGA) 0/1, and ≥ 4-point reduction in weekly average of daily peak pruritus Numerical Rating Scale (PP-NRS) score. RESULTS: In elderly patients at Week 16, response rates for stapokibart versus placebo were 56.0% vs. 14.0% for EASI-75 (p < 0.0001), 40.0% vs. 7.0% for IGA 0/1 (p = 0.0003), and 32.0% vs. 7.0% for ≥ 4-point reduction in weekly average of daily PP-NRS (p = 0.0023). In non-elderly patients, corresponding response rates were 69.7% vs. 28.3%, 45.3% vs. 18.0%, and 36.8% vs. 12.7%, respectively (all p < 0.0001). Within both age subgroups, progressive improvements across all efficacy measures were observed during the maintenance treatment period. The incidence of treatment-emergent adverse events was similar between stapokibart and placebo groups during the 16-week treatment period, regardless of age. CONCLUSION: Stapokibart was effective and had a favorable safety profile in elderly patients with moderate-to-severe AD.
1 个 Figure · 4 个 KM 面板
FIGURE 1 Response rates of (A) EASI‐75, (B) EASI‐90, (C) IGA 0/1, and (D) PP‐NRS score in elderly patients ( n = 93) and non‐elderly patients ( n = 406) during weeks 0–52. E, elderly; EASI‐75/90, ≥ 75%/90% improvement in Eczema Area and Severity Index score; IGA 0/1, Investigator's Global Assessment score of 0 or 1; NE, non‐elderly; PBO, placebo; PP‐NRS, peak pruritus Numerical Rating Scale.
FIGURE 1 · Panel A
Panel A 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 1 · Panel B
Panel B 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 1 · Panel C
Panel C 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 1 · Panel D
Panel D 是同一 FIGURE 1 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。